Patel Nishant, Yopp Adam C, Singal Amit G
From the Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System; and Harold C. Simmons Cancer Center, and the Departments of Surgery and Clinical Sciences, UT Southwestern Medical Center, Dallas, Texas.
From the Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System; and Harold C. Simmons Cancer Center, and the Departments of Surgery and Clinical Sciences, UT Southwestern Medical Center, Dallas, Texas. From the Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System; and Harold C. Simmons Cancer Center, and the Departments of Surgery and Clinical Sciences, UT Southwestern Medical Center, Dallas, Texas.
J Natl Compr Canc Netw. 2015 May;13(5):543-9. doi: 10.6004/jnccn.2015.0074.
Most patients with hepatocellular carcinoma (HCC) present at advanced stages. The prevalence and clinical impact of delays during diagnostic evaluation among patients with HCC is unclear.
To identify and characterize factors associated with diagnostic delays among patients with HCC.
Records were reviewed for consecutive patients with cirrhosis and HCC at a large urban hospital between January 2005 and July 2012. Time from presentation to diagnosis was determined using Kaplan-Meier analysis. Diagnostic delay was defined as time to diagnosis exceeding 3 months, and multivariate logistic regression was used to identify correlates of diagnostic delays.
Among 457 patients with HCC, 226 (49.5%) were diagnosed as outpatients. Among these, median time-to-diagnosis was 2.2 months, with 87 patients (38.5%) experiencing a diagnostic delay. Diagnostic delays were positively associated with the presence of hepatic encephalopathy (odds ratio [OR], 2.29; 95% CI, 1.03-5.07) and negatively associated with presentation after implementation of the electronic medical records (EMR) (OR, 0.28; 95% CI, 0.15-0.52) and presentation with an abnormal ultrasound (OR, 0.36; 95% CI, 0.19-0.67) on multivariate analysis. Higher rates of diagnostic delays were observed among those with hepatic encephalopathy (56% vs 35%), whereas lower rates were seen in those who presented after EMR implementation (26% vs 60%) and those who presented with an abnormal ultrasound with or without an elevated alpha fetoprotein level (27% vs 50%). Among 49 patients with mass-forming HCC and diagnostic delay, 18% had interval tumor growth of 2 cm or greater.
Nearly 20% of patients with HCC wait more than 3 months from presentation to diagnosis, which can contribute to interval tumor growth.
大多数肝细胞癌(HCC)患者就诊时已处于晚期。HCC患者诊断评估过程中延误的发生率及其临床影响尚不清楚。
确定并描述与HCC患者诊断延误相关的因素。
回顾了2005年1月至2012年7月间一家大型城市医院连续收治的肝硬化和HCC患者的记录。采用Kaplan-Meier分析确定从就诊到诊断的时间。诊断延误定义为诊断时间超过3个月,并使用多因素逻辑回归分析来确定诊断延误的相关因素。
在457例HCC患者中,226例(49.5%)为门诊诊断。其中,诊断的中位时间为2.2个月,87例患者(38.5%)经历了诊断延误。诊断延误与肝性脑病的存在呈正相关(比值比[OR],2.29;95%可信区间[CI],1.03 - 5.07),与电子病历(EMR)实施后就诊呈负相关(OR,0.28;95%CI,0.15 - 0.52),在多因素分析中与超声异常就诊也呈负相关(OR,0.36;95%CI,0.19 - 0.67)。肝性脑病患者的诊断延误率较高(56%对35%),而EMR实施后就诊的患者以及超声异常就诊(无论甲胎蛋白水平是否升高)的患者诊断延误率较低(26%对60%以及27%对50%)。在49例有肿块形成的HCC且诊断延误的患者中,18%的患者肿瘤在间隔期生长了2 cm或更大。
近20%的HCC患者从就诊到诊断等待超过3个月,这可能导致肿瘤在间隔期生长。